Shenzhen - Delayed Quote CNY

Huaxia Eye Hospital Group Co.,Ltd. (301267.SZ)

Compare
20.81 -1.09 (-4.98%)
At close: November 22 at 3:04 PM GMT+8
Loading Chart for 301267.SZ
DELL
  • Previous Close 21.90
  • Open 22.90
  • Bid 20.83 x --
  • Ask 20.84 x --
  • Day's Range 20.80 - 21.95
  • 52 Week Range 15.90 - 40.33
  • Volume 5,801,997
  • Avg. Volume 7,253,477
  • Market Cap (intraday) 17.48B
  • Beta (5Y Monthly) 0.67
  • PE Ratio (TTM) 33.03
  • EPS (TTM) 0.63
  • Earnings Date --
  • Forward Dividend & Yield 0.11 (0.53%)
  • Ex-Dividend Date Jul 15, 2024
  • 1y Target Est 29.34

Huaxia Eye Hospital Group Co.,Ltd. operates an ophthalmic medical chain in China and internationally. The company provides general ophthalmology diagnosis and treatment services for patients with ophthalmic diseases. It offers services in the areas of refractive surgery, optometry, pediatric strabismus, cataract, fundus disease, ocular surface and corneal disease, glaucoma, eye trauma, and eye plastic surgery. The company was founded in 1997 and is based in Xiamen, China.

www.huaxiaeye.com

7,613

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 301267.SZ

View More

Performance Overview: 301267.SZ

Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

301267.SZ
34.80%
SSE Composite Index
9.82%

1-Year Return

301267.SZ
47.43%
SSE Composite Index
6.49%

3-Year Return

301267.SZ
55.41%
SSE Composite Index
6.15%

5-Year Return

301267.SZ
55.41%
SSE Composite Index
6.15%

Compare To: 301267.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 301267.SZ

View More

Valuation Measures

Annual
As of 11/22/2024
  • Market Cap

    17.48B

  • Enterprise Value

    14.67B

  • Trailing P/E

    33.03

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.28

  • Price/Book (mrq)

    3.01

  • Enterprise Value/Revenue

    3.58

  • Enterprise Value/EBITDA

    19.70

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    12.94%

  • Return on Assets (ttm)

    5.62%

  • Return on Equity (ttm)

    9.46%

  • Revenue (ttm)

    4.09B

  • Net Income Avi to Common (ttm)

    529.41M

  • Diluted EPS (ttm)

    0.63

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.85B

  • Total Debt/Equity (mrq)

    17.14%

  • Levered Free Cash Flow (ttm)

    224.11M

Research Analysis: 301267.SZ

View More

Company Insights: 301267.SZ

Research Reports: 301267.SZ

View More

People Also Watch